LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Accueil・Liste d'Actions・Incyte Corp

Incyte Corp

Fermé

Secteur Soins de santé

61.27 -2.56

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

61.17

Max

61.81

Chiffres clés
By Trading Economics
Revenu	-614M -445M
Ventes	159M 1B
P/E Moyenne du Secteur	18.37 103.001
BPA	-1.82
Marge bénéficiaire	-42.75
Employés	2,524
EBITDA	-626M -367M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+13.45 upside

Dividendes
By Dow Jones
Prochains Résultats	29 oct. 2024

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	15B
Ouverture précédente	63.83
Clôture précédente	61.27

Sentiment de l'Actualité

By Acuity

93%

2 / 365 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

61.15 / 65.63 Support & Résistance

Incyte Corp Graphique

Actualités Associées

5 févr. 2024, 16:29 UTC

Acquisitions, Fusions, Rachats

Novartis in Lead to Acquire Cancer-Drug Maker MorphoSys, Reuters Reports

20 févr. 2024, 10:30 UTC

Acquisitions, Fusions, Rachats

An Executive Bought a Rival's Stock. The SEC Says That's Insider Trading. -- WSJ

5 févr. 2024, 23:54 UTC

Acquisitions, Fusions, Rachats

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion -- IBD

Comparaison

Variation de prix

Incyte Corp prévision

Objectif de Prix

By TipRanks

13.45% hausse

Prévisions sur 12 Mois

Moyen 71.43 USD 13.45%

Haut 92 USD

Bas 48 USD

Basé sur 16 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

16 ratings

Achat

Maintien

Vente

Basé sur 16 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

61.15 / 65.63Support & Résistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Sentiment

By Acuity

2 / 365Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Incyte Corp

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.